Abstract
Cardiovascular diseases are managed through multi drug regimens. For better patient compliance and cost effectiveness, desired therapeutic efficacy is achieved through combination of more than two drugs in single dosage form. Nebivolol Hydrochloride is β1 receptor blocker and Pravastatin sodium exhibits its pharmacological action through inhibition of cholesterol synthesis. Both drugs are therapeutically compatible and can be administered in single dose formulation. A review of the literature found that there was no effective strategy for the selected drug combination. As a result, an attempt was made to establish a simple, efficient, sensitive, specific, and rapid method for simultaneously estimating Pravastatin sodium and Nebivolol hydrochloride in bulk drugs using RP-HPLC.Column C-18 (Shim-pack) 250 x 4.6 mm, particle size 5 m, mobile phase acetonitrile and water in the ratio 20:80 at 257 nm were found to be the optimal chromatographic conditions. Pravastatin sodium and Nebivolol hydrochloride had retention times of 2.092 and 3.623 minutes, respectively, with average percentage recovery of 99.38% and 99.54%, respectively.The proposed technique was found to be in accordance with the guidelines of the International Conference on Harmonization (ICH).
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
